Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||PF-00562271||Preclinical - Cell line xenograft||Actionable||In a preclinical study, PF-00562271 inhibited PTK2 (FAK) phosphorylation and growth of multiple tumor cell types in cell line xenograft models (PMID: 18339875).||18339875|
|Unknown unknown||Advanced Solid Tumor||not applicable||PF-00562271||Phase I||Actionable||In a Phase I trial, PF-00562271 was well-tolerated and resulted in stable disease in 34% (31/91) of patients with advanced solid tumors as well as a metabolic response of 50% (7/14) (PMID: 22454420).||22454420|
|PubMed Id||Reference Title||Details|
|(18339875)||Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.||Full reference...|
|(22454420)||Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.||Full reference...|